KR101521861B1 - Alk 억제제의 사용 방법 - Google Patents
Alk 억제제의 사용 방법 Download PDFInfo
- Publication number
- KR101521861B1 KR101521861B1 KR1020137023001A KR20137023001A KR101521861B1 KR 101521861 B1 KR101521861 B1 KR 101521861B1 KR 1020137023001 A KR1020137023001 A KR 1020137023001A KR 20137023001 A KR20137023001 A KR 20137023001A KR 101521861 B1 KR101521861 B1 KR 101521861B1
- Authority
- KR
- South Korea
- Prior art keywords
- alk
- delete delete
- compound
- eml4
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438878P | 2011-02-02 | 2011-02-02 | |
| US61/438,878 | 2011-02-02 | ||
| PCT/US2012/023669 WO2012106540A1 (en) | 2011-02-02 | 2012-02-02 | Methods of using alk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130121174A KR20130121174A (ko) | 2013-11-05 |
| KR101521861B1 true KR101521861B1 (ko) | 2015-05-21 |
Family
ID=45582065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137023001A Active KR101521861B1 (ko) | 2011-02-02 | 2012-02-02 | Alk 억제제의 사용 방법 |
Country Status (22)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| AU2013341271A1 (en) * | 2012-11-07 | 2015-05-14 | Novartis Ag | Combination therapy |
| CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
| ITMI20131124A1 (it) * | 2013-07-04 | 2015-01-05 | Univ Milano Bicocca | 2-acilamminotiazoli per il trattamento del cancro |
| JP6510510B2 (ja) * | 2013-07-11 | 2019-05-08 | ベータ ファーマシューティカルズ カンパニー リミテッド | プロテインチロシンキナーゼモジュレーター及び使用方法 |
| US20160361314A1 (en) * | 2013-08-28 | 2016-12-15 | Novartis Ag | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| AU2014372166B2 (en) * | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| US10053458B2 (en) * | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| CN106220644B (zh) | 2015-04-24 | 2020-07-31 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| CN106220608B (zh) * | 2016-07-25 | 2018-11-27 | 安润医药科技(苏州)有限公司 | 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途 |
| CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| SG11201901251SA (en) * | 2016-08-29 | 2019-03-28 | Univ Michigan Regents | Aminopyrimidines as alk inhibitors |
| CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| ATE542801T1 (de) * | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2008007368A2 (en) | 2006-07-10 | 2008-01-17 | Rf Dynamics Ltd. | Food preparation |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| EA019941B1 (ru) * | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2009233964B2 (en) * | 2008-04-07 | 2012-06-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2012
- 2012-02-02 PT PT127036705T patent/PT2670401E/pt unknown
- 2012-02-02 EA EA201391114A patent/EA023404B1/ru not_active IP Right Cessation
- 2012-02-02 KR KR1020137023001A patent/KR101521861B1/ko active Active
- 2012-02-02 CA CA2824092A patent/CA2824092C/en active Active
- 2012-02-02 PL PL12703670T patent/PL2670401T3/pl unknown
- 2012-02-02 HR HRP20150946TT patent/HRP20150946T1/hr unknown
- 2012-02-02 US US13/981,046 patent/US8703787B2/en active Active
- 2012-02-02 AU AU2012212142A patent/AU2012212142B2/en active Active
- 2012-02-02 CN CN201280007465.9A patent/CN103458881B/zh active Active
- 2012-02-02 JP JP2013552637A patent/JP5837095B2/ja active Active
- 2012-02-02 ME MEP-2015-127A patent/ME02200B/me unknown
- 2012-02-02 BR BR112013019643-2A patent/BR112013019643B1/pt active IP Right Grant
- 2012-02-02 SI SI201230285T patent/SI2670401T1/sl unknown
- 2012-02-02 RS RS20150563A patent/RS54189B1/sr unknown
- 2012-02-02 HU HUE12703670A patent/HUE025395T2/en unknown
- 2012-02-02 EP EP12703670.5A patent/EP2670401B1/en active Active
- 2012-02-02 MX MX2013008791A patent/MX2013008791A/es unknown
- 2012-02-02 WO PCT/US2012/023669 patent/WO2012106540A1/en not_active Ceased
- 2012-02-02 DK DK12703670.5T patent/DK2670401T3/en active
- 2012-02-02 ES ES12703670.5T patent/ES2543567T3/es active Active
-
2015
- 2015-08-28 CY CY20151100758T patent/CY1116662T1/el unknown
- 2015-11-30 SM SM201500300T patent/SMT201500300B/it unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| Neoplasia. Vol.13(1), pp.1-11 * |
| Neoplasia. Vol.13(1), pp.1-11* |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391114A1 (ru) | 2013-12-30 |
| CA2824092C (en) | 2020-06-30 |
| AU2012212142A1 (en) | 2013-08-15 |
| ME02200B (me) | 2016-02-20 |
| JP2014504646A (ja) | 2014-02-24 |
| CA2824092A1 (en) | 2012-08-09 |
| DK2670401T3 (en) | 2015-09-07 |
| EP2670401B1 (en) | 2015-06-10 |
| KR20130121174A (ko) | 2013-11-05 |
| JP5837095B2 (ja) | 2015-12-24 |
| HUE025395T2 (en) | 2016-02-29 |
| US20130296357A1 (en) | 2013-11-07 |
| CN103458881B (zh) | 2015-08-12 |
| BR112013019643B1 (pt) | 2022-04-19 |
| CN103458881A (zh) | 2013-12-18 |
| WO2012106540A1 (en) | 2012-08-09 |
| AU2012212142B2 (en) | 2015-09-24 |
| RS54189B1 (sr) | 2015-12-31 |
| SMT201500300B (it) | 2016-01-08 |
| PT2670401E (pt) | 2015-10-12 |
| BR112013019643A2 (pt) | 2016-10-04 |
| PL2670401T3 (pl) | 2015-11-30 |
| SI2670401T1 (sl) | 2015-10-30 |
| HRP20150946T1 (hr) | 2015-10-09 |
| MX2013008791A (es) | 2013-10-07 |
| EA023404B1 (ru) | 2016-05-31 |
| CY1116662T1 (el) | 2017-03-15 |
| US8703787B2 (en) | 2014-04-22 |
| EP2670401A1 (en) | 2013-12-11 |
| ES2543567T3 (es) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5837095B2 (ja) | Alk阻害剤の使用方法 | |
| JP5852173B2 (ja) | チロシンキナーゼ活性阻害作用を有する新規な縮合ピリミジン誘導体 | |
| CN101137382B (zh) | 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂 | |
| TWI617556B (zh) | 經炔基取代之喹唑啉化合物及其使用方法 | |
| JP2021501145A (ja) | 血液学的障害を治療するための化合物および組成物 | |
| US12414945B2 (en) | Therapeutic agent for breast cancer | |
| CN107949387A (zh) | 用谷氨酰胺酶抑制剂治疗肺癌 | |
| KR20230154793A (ko) | 암 치료를 위한 병용 요법 | |
| JP2019511554A (ja) | 静止細胞標的化およびegfr阻害剤を用いた新生物の処置のための組み合わせ | |
| KR20250069693A (ko) | 암 치료 | |
| KR20210038906A (ko) | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 | |
| TW201806600A (zh) | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 | |
| CA3196283A1 (en) | Csf1r kinase inhibitor and use thereof | |
| KR20230152652A (ko) | 암 치료를 위한 병용 요법 | |
| KR20210126654A (ko) | 암 치료 | |
| JP2024514098A (ja) | ErbB2突然変異体を標的とする阻害薬の調製における化合物の使用 | |
| EP3012248B1 (en) | Substance having tyrosine kinase inhibitory activity and preparation method and use thereof | |
| CN117098537A (zh) | 用于癌症治疗的联合疗法 | |
| TW202140005A (zh) | 用於治療發炎疾病之新穎藥物 | |
| CN103705517A (zh) | Src激酶抑制剂对溶骨性病变的抑制 | |
| WO2016052081A1 (ja) | 癌細胞増殖抑制剤、抗癌剤、及びこれらのスクリーニング方法、並びに新規化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20180427 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190429 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-5-5-R10-R17-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 11 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 12 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 12 |